Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard ...
Immuneering (NASDAQ:IMRX) provided an update from its ongoing Phase 2A trial of atebumetanib plus modified gemcitabine and ...
Camrelizumab plus chemotherapy doubled the five-year survival rate in advanced squamous lung cancer to 27.8%, reducing mortality risk by 43%. The CameL-sq trial demonstrated camrelizumab's efficacy as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback